Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63,492,063
-
Total 13F shares
-
58,588,386
-
Share change
-
-1,134,433
-
Total reported value
-
$2,765,378,029
-
Put/Call ratio
-
82%
-
Price per share
-
$47.20
-
Number of holders
-
129
-
Value change
-
-$36,637,318
-
Number of buys
-
57
-
Number of sells
-
78
Institutional Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q2 2025
As of 30 Jun 2025,
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,588,386 shares.
The largest 10 holders included
BVF INC/IL, Cormorant Asset Management, LP, FMR LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, WESTFIELD CAPITAL MANAGEMENT CO LP, FEDERATED HERMES, INC., and ALLIANCEBERNSTEIN L.P..
This page lists
129
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.